DataMeds AI Enters Lucrative Custom Medicine Market with First Therapy Sale

New York, Monday, 9 November 2026.
DataMeds AI completed its first commercial sale of unapproved custom therapies, leveraging federal regulatory flexibility to tap into an expanding compounding market projected to surpass $31 billion.